Tags

Type your tag names separated by a space and hit enter

Statins dose-dependently exert a chemopreventive effect against lung cancer in COPD patients: a population-based cohort study.
Oncotarget. 2016 Sep 13; 7(37):59618-59629.O

Abstract

PURPOSE

Chronic obstructive pulmonary disease (COPD) is associated with increased lung cancer risk. We evaluated the association of statin use with lung cancer risk in COPD patients and identified which statins possess the highest chemopreventive potential.

RESULTS

After adjustment for age, sex, CCI, diabetes, hypertension, dyslipidemia, urbanization level, and monthly income according to propensity scores, lung cancer risk in the statin users was lower than that in the statin nonusers (adjusted hazard ratio [aHR] = 0.37). Of the individual statins, lovastatin and fluvastatin did not reduce lung cancer risk significantly. By contrast, lung cancer risk in patients using rosuvastatin, simvastatin, atorvastatin, and pravastatin was significantly lower than that in statin nonusers (aHRs = 0.41, 0.44, 0.52, and 0.58, respectively). Statins dose-dependently reduced lung cancer risk in all subgroups and the main model with additional covariates (nonstatin drug use).

MATERIALS AND METHODS

The study cohort comprised all patients diagnosed with COPD at health care facilities in Taiwan (n = 116,017) between January 1, 2001 and December 31, 2012. Our final study cohort comprised 43,802 COPD patients: 10,086 used statins, whereas 33,716 did not. Patients were followed up to assess lung cancer risk or protective factors. In addition, we also considered demographic characteristics, namely age, sex, comorbidities (diabetes, hypertension, dyslipidemia, and Charlson comorbidity index [CCI]), urbanization level, monthly income, and nonstatin drug use. The index date of statin use was the COPD confirmation date. To examine the dose-response relationship, we categorized statin use into four groups in each cohort: < 28, 28-90, 91-365, and > 365 cumulative defined daily doses (cDDDs). Patients receiving < 28 cDDDs were defined as nonstatin users.

CONCLUSIONS

Statins dose-dependently exert a significant chemopreventive effect against lung cancer in COPD patients. Rosuvastatin, simvastatin, and atorvastatin exhibited the highest chemopreventive potential.

Authors+Show Affiliations

Division of Cardiovascular Medicine, Department of Internal Medicine, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan. Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.Division of Cardiovascular Medicine, Department of Internal Medicine, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan.Division of Cardiovascular Medicine, Department of Internal Medicine, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan.Division of Cardiovascular Medicine, Department of Internal Medicine, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan.Division of Cardiovascular Medicine, Department of Internal Medicine, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan. Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.Division of Cardiovascular Medicine, Department of Internal Medicine, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan. Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.Division of Cardiovascular Medicine, Department of Internal Medicine, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan.Institute of Toxicology, College of Medicine, National Taiwan University, Taipei, Taiwan. Department of Radiation Oncology, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan. Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan. Department of Biotechnology, Hungkuang University, Taichung, Taiwan.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

27517752

Citation

Liu, Ju-Chi, et al. "Statins Dose-dependently Exert a Chemopreventive Effect Against Lung Cancer in COPD Patients: a Population-based Cohort Study." Oncotarget, vol. 7, no. 37, 2016, pp. 59618-59629.
Liu JC, Yang TY, Hsu YP, et al. Statins dose-dependently exert a chemopreventive effect against lung cancer in COPD patients: a population-based cohort study. Oncotarget. 2016;7(37):59618-59629.
Liu, J. C., Yang, T. Y., Hsu, Y. P., Hao, W. R., Kao, P. F., Sung, L. C., Chen, C. C., & Wu, S. Y. (2016). Statins dose-dependently exert a chemopreventive effect against lung cancer in COPD patients: a population-based cohort study. Oncotarget, 7(37), 59618-59629. https://doi.org/10.18632/oncotarget.11162
Liu JC, et al. Statins Dose-dependently Exert a Chemopreventive Effect Against Lung Cancer in COPD Patients: a Population-based Cohort Study. Oncotarget. 2016 Sep 13;7(37):59618-59629. PubMed PMID: 27517752.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Statins dose-dependently exert a chemopreventive effect against lung cancer in COPD patients: a population-based cohort study. AU - Liu,Ju-Chi, AU - Yang,Tsung-Yeh, AU - Hsu,Yi-Ping, AU - Hao,Wen-Rui, AU - Kao,Pai-Feng, AU - Sung,Li-Chin, AU - Chen,Chun-Chao, AU - Wu,Szu-Yuan, PY - 2016/03/09/received PY - 2016/07/09/accepted PY - 2016/8/16/pubmed PY - 2018/2/7/medline PY - 2016/8/13/entrez KW - COPD KW - lung cancer KW - statins SP - 59618 EP - 59629 JF - Oncotarget JO - Oncotarget VL - 7 IS - 37 N2 - PURPOSE: Chronic obstructive pulmonary disease (COPD) is associated with increased lung cancer risk. We evaluated the association of statin use with lung cancer risk in COPD patients and identified which statins possess the highest chemopreventive potential. RESULTS: After adjustment for age, sex, CCI, diabetes, hypertension, dyslipidemia, urbanization level, and monthly income according to propensity scores, lung cancer risk in the statin users was lower than that in the statin nonusers (adjusted hazard ratio [aHR] = 0.37). Of the individual statins, lovastatin and fluvastatin did not reduce lung cancer risk significantly. By contrast, lung cancer risk in patients using rosuvastatin, simvastatin, atorvastatin, and pravastatin was significantly lower than that in statin nonusers (aHRs = 0.41, 0.44, 0.52, and 0.58, respectively). Statins dose-dependently reduced lung cancer risk in all subgroups and the main model with additional covariates (nonstatin drug use). MATERIALS AND METHODS: The study cohort comprised all patients diagnosed with COPD at health care facilities in Taiwan (n = 116,017) between January 1, 2001 and December 31, 2012. Our final study cohort comprised 43,802 COPD patients: 10,086 used statins, whereas 33,716 did not. Patients were followed up to assess lung cancer risk or protective factors. In addition, we also considered demographic characteristics, namely age, sex, comorbidities (diabetes, hypertension, dyslipidemia, and Charlson comorbidity index [CCI]), urbanization level, monthly income, and nonstatin drug use. The index date of statin use was the COPD confirmation date. To examine the dose-response relationship, we categorized statin use into four groups in each cohort: < 28, 28-90, 91-365, and > 365 cumulative defined daily doses (cDDDs). Patients receiving < 28 cDDDs were defined as nonstatin users. CONCLUSIONS: Statins dose-dependently exert a significant chemopreventive effect against lung cancer in COPD patients. Rosuvastatin, simvastatin, and atorvastatin exhibited the highest chemopreventive potential. SN - 1949-2553 UR - https://www.unboundmedicine.com/medline/citation/27517752/Statins_dose_dependently_exert_a_chemopreventive_effect_against_lung_cancer_in_COPD_patients:_a_population_based_cohort_study_ L2 - http://www.impactjournals.com/oncotarget/misc/linkedout.php?pii=11162 DB - PRIME DP - Unbound Medicine ER -